Back
“Biogen's Alzheimer's pipeline just got a second leg. Its tau-targeting drug matched the efficacy benchmark set by the already-approved amyloid drugs, opening a new treatment class that could compound the company's position in a massive and growing market.”
Source
Adam Feuerstein ✡️X“Biogen Alzheimer's drug slowed cognitive decline…”span
“$BIIB tau drug results just revealed at #AAIC26”
Performance
Entry$210.50
Current$191.95
Since call-8.81%
Confidence72%
How this was scored
Entry$210.50Jul 14, 2026 · 13:17 UTC · paste.trade
Current$191.95Jul 15, 2026 · 11:46 UTC · Finnhub
Horizonnot specifiedparsed as default-30d
Verdict bandWIN ≥ +2% · LOSS ≤ −2%
Prices are point-in-time snapshots from the named provider. The verdict compares the return since entry against the band above.